Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/47804
Title: | Merkel cell carcinoma in Turkey: A multicentric study | Authors: | Yıldız, Fatih Demirci, Umut Küçükard, Ahmet Büyükşimsek, Mahmut Sakalar,Teoman Topçu, Turkan Aslan, Ferit Tufan, Gülnihal Aydın, Övgü Turna, Hande Babacan, Nalan Başoğlu, Tuğba Kurt, Bediz Yıldız, Birol Eren, Tülay Demiray, Atike Gümüşay, Özge Arslan, Çağatay Özdemir, Nuriye Ürün, Yüksel Baykara, Meltem Turan, Nedim Uysal, Mükremin Bilici, Ahmet Kavgacı, Halil Cicin, İrfan Kılıçkap, Saadettin Paydaş, Semra |
Keywords: | CK20 merkel cell carcinoma neuroendocrin carcinoma skin carcinoma avelumab carboplatin cisplatin cyclophosphamide cytokeratin 20 doxorubicin etoposide vincristine adjuvant radiotherapy adult aged Article cancer adjuvant therapy cancer combination chemotherapy cancer radiotherapy cancer recurrence cancer staging cancer survival chemoradiotherapy clinical evaluation disease free survival distant metastasis female follow up histopathology human immunohistochemistry immunosuppressive treatment limb tumor major clinical study male merkel cell carcinoma multicenter study overall survival progression free survival retrospective study treatment outcome Turkey (republic) very elderly aftercare clinical trial epidemiology incidence merkel cell carcinoma middle aged mortality prevention and control procedures skin tumor tumor recurrence turkey (bird) Adult Aftercare Aged Aged, 80 and over Carcinoma, Merkel Cell Chemoradiotherapy Disease-Free Survival Female Humans Incidence Male Middle Aged Neoplasm Recurrence, Local Neoplasm Staging Progression-Free Survival Retrospective Studies Skin Neoplasms Turkey |
Publisher: | Wolters Kluwer Medknow Publications | Abstract: | Background: Merkel cell carcinoma (MCC) is a rare but highly aggressive neuroendocrine carcinoma of the skin. In this study, we aimed to evaluate the clinicopathologic characteristics, treatment outcomes, and survival of MCC cases in Turkey. Materials and Methods: The patients diagnosed with MCC between 1999 and 2018 at twenty different centers in Turkey were included in the study. Patient and tumor characteristics and adjuvant and metastatis treatment outcomes were analyzed retrospectively. Results: The median age of totally 89 patients was 70 (26-93). The most common primary location was lower limbs (n = 29, 32.5%). Immunohistochemically, CK20 positivity was present in 59 patients (66.3%). Only two patients had secondary malignancy. The majority of the patients (n = 76, 85.4%) were diagnosed at the localized stage. Surgery was performed for all patients in the early stage, and adjuvant radiotherapy or/and chemotherapy was applied to 52.6% (n = 40) of nonmetastatic patients. The median follow-up was 29 months. Recurrence developed in 21 (27.6%) of the 76 patients who presented with local or regional disease. Two-year disease-free survival (DFS) was 68.1% and 5-year DFS was 62.0% for localized stage. The 5-year DFS was similar for patients receiving adjuvant treatment (chemotherapy, radiotherapy, or sequential chemoradiotherapy) and without adjuvant therapy (P > 0.05). Two-year overall survival in patients who presented with localized disease was 71.3% and 18.5% in metastatic patients (P < 0.001). In the metastatic stage, platinum/etoposide combination was the most preferred combination regimen. Median progression-free survival (PFS) in first-line chemotherapy was 7 months (95% confidence interval: 3.5-10.5 months; standart error: 1.78). Conclusions: Although MCC is rare in Turkey, the incidence is increasing. Gender, CK20 status, tumor size, lymph node involvement, and adjuvant treatment were not associated with recurrence. © 2021 Wolters Kluwer Medknow Publications. All rights reserved. | URI: | https://doi.org/10.4103/jcrt.JCRT-950-19 https://hdl.handle.net/11499/47804 |
ISSN: | 0973-1482 |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu |
Show full item record
CORE Recommender
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.